References analysis of the Wikipedia article "Marc Lacroix (biochemist)" in the English version

doi.org

Siwek, B; Larsimont D; Lacroix M; Body JJ (1998). "Establishment and characterization of three new breast-cancer cell lines". International Journal of Cancer. 76 (5): 677–683. doi:10.1002/(SICI)1097-0215(19980529)76:5<677::AID-IJC11>3.0.CO;2-1. PMID 9610725.

Lacroix, M; Zammatteo N; Remacle J; Leclercq G. (2002). "A low-density DNA microarray for analysis of markers in breast cancer". International Journal of Biological Markers. 17 (1): 5–23. doi:10.1177/172460080201700102. PMID 11936587.

Lacroix, M; Leclercq G. (2004). "Relevance of breast cancer cell lines as models for breast tumours: an update". Breast Cancer Research and Treatment. 83 (3): 249–289. doi:10.1023/B:BREA.0000014042.54925.cc. PMID 14758095. S2CID 207628369.

Lacroix, M; Haibe-Kains B; Hennuy B; Laes JF; Lallemand F; Gonze I; Cardoso F; Piccart M; Leclercq G; Sotiriou C. (2004). "Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes". Oncology Reports. 12 (4): 701–707. doi:10.3892/or.12.4.701. PMID 15375488. S2CID 21227327.

Lacroix, M; Leclercq G; et al. (BreastMed Consortium) (2005). "The "portrait" of hereditary breast cancer". Breast Cancer Research and Treatment. 89 (3): 297–304. doi:10.1007/s10549-004-2172-4. PMID 15754129. S2CID 23327569.

Lacroix, M; Toillon RA; Leclercq G. (2006). "P53 and breast cancer, an update". Endocrine-Related Cancer. 13 (2): 293–325. doi:10.1677/erc.1.01172. PMID 16728565.

Lacroix., M (2006). "Significance, detection and markers of disseminated breast cancer cells". Endocrine-Related Cancer. 13 (4): 1033–1067. doi:10.1677/ERC-06-0001. PMID 17158753.

Lacroix., M (2008). "Persistent use of "false" cell lines". International Journal of Cancer. 122 (1): 1–4. doi:10.1002/ijc.23233. PMID 17960586.

Lacroix, M; Siwek B; Marie PJ; Body JJ. (1998). "Production and regulation of interleukin-11 by breast cancer cells". Cancer Letters. 127 (1–2): 29–35. doi:10.1016/S0304-3835(97)00542-9. PMID 9619855.

Sotiriou, C; Lacroix M; Lespagnard L; Larsimont D; Paesmans M; Body JJ. (2001). "Interleukins-6 and-11 expression in primary breast cancer and subsequent development of bone metastases". Cancer Letters. 169 (1): 87–95. doi:10.1016/S0304-3835(01)00524-9. PMID 11410329.

Lacroix, M; Siwek B; Body JJ. (1996). "Effects of secretory products of breast cancer cells on osteoblast-like cells". Breast Cancer Research and Treatment. 38 (2): 209–216. doi:10.1007/BF01806675. PMID 8861839. S2CID 25572056.

Siwek, B; Lacroix M; DePollak C; Marie P; Body JJ. (1997). "Secretory products of breast cancer cells specifically affect human osteoblastic cells: Partial characterization of active factors". Journal of Bone and Mineral Research. 12 (4): 552–560. doi:10.1359/jbmr.1997.12.4.552. PMID 9101366. S2CID 46565128.

Lacroix, M; Lacroix M; Marie PJ; Body JJ. (2000). "Protein production by osteoblasts: modulation by breast cancer cell-derived factors". Breast Cancer Research and Treatment. 61 (1): 59–67. doi:10.1023/A:1006408916224. PMID 10930090. S2CID 9512363.

Lacroix, M; Body JJ. (1997). "Regulation of c-fos and c-jun expression by calcitonin in human breast cancer cells". Calcified Tissue International. 60 (6): 513–519. doi:10.1007/s002239900273. PMID 9164825. S2CID 34337293.

Lacroix, M; Siwek B; Body JJ. (1998). "Breast cancer cell response to calcitonin: Modulation by growth-regulating agents". European Journal of Pharmacology. 344 (2–3): 279–286. doi:10.1016/S0014-2999(97)01578-1. PMID 9600664.

Jin, L; Borras M; Lacroix M; Legros N; Leclercq G. (1995). "Antiestrogenic activity of 2 11-beta-estradiol derivatives on MCF-7 breast cancer cells". Steroids. 60 (8): 512–518. doi:10.1016/0039-128X(95)00079-6. PMID 8539793. S2CID 9007067.

Borras, M; Lacroix M; Legros N; Leclercq G. (1997). "Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers". Cancer Letters. 120 (1): 23–30. doi:10.1016/S0304-3835(97)00285-1. PMID 9570382.

Maaroufi, Y; Lacroix M; Lespagnard L; Journe F; Larsimont D; Leclercq G. (2000). "Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis". Breast Cancer Research. 2 (6): 444–454. doi:10.1186/bcr92. PMC 13922. PMID 11056692.

Lacroix, M; Querton G; Hennebert P; Larsimont D; Leclercq G. (2001). "Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immmocytochemical assay, and northern blot: a comparison". Breast Cancer Research and Treatment. 67 (3): 263–271. doi:10.1023/A:1017946810277. PMID 11561772. S2CID 631103.

Rivas, A; Lacroix M; Olea-Serrano F; Laios I; Leclercq G; Olea N. (2002). "Estrogenic effect of a series of bisphenol analogues on gene and protein expression in MCF-7 breast cancer cells". Journal of Steroid Biochemistry and Molecular Biology. 82 (1): 45–53. doi:10.1016/S0960-0760(02)00146-2. PMID 12429138. S2CID 9619137.

Lacroix, M; Leclercq G. (2004). "About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer". Molecular and Cellular Endocrinology. 219 (1–2): 1–7. doi:10.1016/j.mce.2004.02.021. PMID 15149721. S2CID 38557047.

Toillon RA, Magné N, Laios I, Lacroix M, Duvillier H, Lagneaux L, Devriendt D, Van Houtte P, Leclercq G (2005). "Interaction between estrogen receptor α, ionizing radiation and (anti-) estrogens in breast cancer cells". Breast Cancer Research and Treatment. 93 (3): 207–215. doi:10.1007/s10549-005-5148-0. PMID 16136271. S2CID 6016940.

Leclercq, G; Lacroix M; Laïos I; Laurent G. (2006). "Estrogen receptor α: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells". Current Cancer Drug Targets. 6 (1): 39–64. CiteSeerX 10.1.1.475.5425. doi:10.2174/156800906775471716. PMID 16475975.

Toillon RA, Magné N, Laïos I, Castadot P, Kinnaert E, Van Houtte P, Desmedt C, Leclercq G, Lacroix M (2007). "Estrogens decrease gamma-rays induced senescence and maintain cell cycle progression in breast cancer cells independently of p53". International Journal of Radiation Oncology, Biology, Physics. 67 (4): 1187–1200. doi:10.1016/j.ijrobp.2006.11.040. PMID 17336220.

Lacroix, M; Toillon RA; Leclercq G. (2004). "Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics". Endocrine-Related Cancer. 11 (3): 497–522. doi:10.1677/erc.1.00758. PMID 15369451.

nih.gov

pubmed.ncbi.nlm.nih.gov

De Longueville F, Lacroix M, Barbuto AM, Bertholet V, Gallo D, Larsimont D, Marcq L, Zammatteo N, Boffe S, Leclercq G, Remacle J (2005). "Molecular characterization of breast cancer cell lines by a low-density microarray". International Journal of Oncology. 27 (4): 881–892. PMID 16142302.

Lacroix, M; Toillon RA; Leclercq G. (2006). "P53 and breast cancer, an update". Endocrine-Related Cancer. 13 (2): 293–325. doi:10.1677/erc.1.01172. PMID 16728565.

Lacroix., M (2006). "Significance, detection and markers of disseminated breast cancer cells". Endocrine-Related Cancer. 13 (4): 1033–1067. doi:10.1677/ERC-06-0001. PMID 17158753.

Lacroix., M (2008). "Persistent use of "false" cell lines". International Journal of Cancer. 122 (1): 1–4. doi:10.1002/ijc.23233. PMID 17960586.

Sotiriou C, Lacroix M, Lagneaux L, Berchem G, Body JJ (1999). "The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and-11". Anticancer Research. 19 (4B): 2997–3006. PMID 10652584.

ncbi.nlm.nih.gov

psu.edu

citeseerx.ist.psu.edu

semanticscholar.org

api.semanticscholar.org

zenodo.org

Marc Lacroix (biochemist) (English Wikipedia)